Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.
Investors are applauding the company's late-stage clinical results for its lead pipeline candidate.
Mixed results from Apellis Pharmaceuticals are good news for Iveric Bio's geographic atrophy program.
ISEE earnings call for the period ending December 31, 2022.
ISEE earnings call for the period ending September 30, 2022.
ISEE earnings call for the period ending June 30, 2022.
ISEE earnings call for the period ending March 31, 2022.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.